Alnylam Pharmaceuticals
Market Cap
US$19.4b
Last Updated
2021/01/22 00:26 UTC
Data Sources
Company Financials +
Executive Summary
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Alnylam Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALNY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ALNY's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
1.0%
ALNY
0.7%
US Biotechs
1.4%
US Market
1 Year Return
41.4%
ALNY
40.9%
US Biotechs
22.6%
US Market
Return vs Industry: ALNY matched the US Biotechs industry which returned 41.5% over the past year.
Return vs Market: ALNY exceeded the US Market which returned 22.8% over the past year.
Shareholder returns
| ALNY | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | 0.7% | 1.4% |
| 30 Day | 20.6% | 5.2% | 4.9% |
| 90 Day | 26.5% | 23.7% | 14.6% |
| 1 Year | 41.4%41.4% | 43.2%40.9% | 25.4%22.6% |
| 3 Year | 24.2%24.2% | 27.1%20.5% | 46.8%37.0% |
| 5 Year | 155.8%155.8% | 58.4%46.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is Alnylam Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
We're Not Very Worried About Alnylam Pharmaceuticals' (NASDAQ:ALNY) Cash Burn Rate1 month ago | Simply Wall St
Update: Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gained 29% In The Last Five YearsValuation
Is Alnylam Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALNY ($166.75) is trading below our estimate of fair value ($339)
Significantly Below Fair Value: ALNY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALNY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALNY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALNY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALNY is overvalued based on its PB Ratio (15.9x) compared to the US Biotechs industry average (4.5x).
Next Steps
Future Growth
How is Alnylam Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
57.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALNY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ALNY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALNY's is expected to become profitable in the next 3 years.
Revenue vs Market: ALNY's revenue (36.7% per year) is forecast to grow faster than the US market (10.5% per year).
High Growth Revenue: ALNY's revenue (36.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALNY is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Alnylam Pharmaceuticals performed over the past 5 years?
-24.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALNY is currently unprofitable.
Growing Profit Margin: ALNY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALNY is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare ALNY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ALNY has a negative Return on Equity (-73.33%), as it is currently unprofitable.
Next Steps
Financial Health
How is Alnylam Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ALNY's short term assets ($2.6B) exceed its short term liabilities ($480.2M).
Long Term Liabilities: ALNY's short term assets ($2.6B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: ALNY is debt free.
Reducing Debt: ALNY had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALNY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALNY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Alnylam Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALNY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average management tenure
CEO
John Maraganore (57 yo)
18.08yrs
Tenure
US$7,317,856
Compensation
Dr. John M. Maraganore, M.D., Ph.D. was an Advisor at Flex Pharma, Inc. Dr. Maraganore has been the Chief Executive Officer and Executive Director at Alnylam Pharmaceuticals, Inc. since December 2002. He h...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.32M) is below average for companies of similar size in the US market ($USD10.55M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 18.08yrs | US$7.32m | 0.17% $ 33.5m | |
| President & COO | 0.25yr | US$3.25m | 0.0045% $ 871.8k | |
| Chief Financial Officer | 1.42yrs | US$6.16m | 0.000050% $ 9.7k | |
| President of Research & Development | 12.08yrs | US$3.10m | 0.013% $ 2.4m | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Senior VP & Chief Scientific Officer | 1.67yrs | no data | no data | |
| Senior VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Executive VP | 6.33yrs | US$5.31m | 0.0023% $ 445.6k | |
| Chief Ethics & Compliance Officer | 0.58yr | no data | no data | |
| Vice President of Global Marketing | 4yrs | no data | no data | |
| Chief Human Resource Officer | 1.67yrs | no data | no data | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | 5.25yrs | no data | no data |
1.7yrs
Average Tenure
57yo
Average Age
Experienced Management: ALNY's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 18.08yrs | US$7.32m | 0.17% $ 33.5m | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | 5.25yrs | no data | no data | |
| Independent Chairman | 5.08yrs | US$505.71k | 0.0034% $ 666.4k | |
| Member of the Scientific Advisory Board | no data | US$475.71k | 0.26% $ 51.2m | |
| Independent Director | 5.08yrs | US$470.71k | 0.024% $ 4.7m | |
| Co-Founder | 18.58yrs | US$495.71k | 0.23% $ 44.5m | |
| Independent Director | 10.08yrs | US$490.71k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$485.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board & Independent Director | 8.75yrs | US$470.71k | 0.0030% $ 583.1k | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.6yrs
Average Tenure
67yo
Average Age
Experienced Board: ALNY's board of directors are considered experienced (7.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.
Top Shareholders
Company Information
Alnylam Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Alnylam Pharmaceuticals, Inc.
- Ticker: ALNY
- Exchange: NasdaqGS
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$19.373b
- Shares outstanding: 116.18m
- Website: https://www.alnylam.com
Number of Employees
Location
- Alnylam Pharmaceuticals, Inc.
- 675 West Kendall Street
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ALNY | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 2004 |
| DUL | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2004 |
| DUL | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | May 2004 |
| 0HD2 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 2004 |
| ALNY * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 2004 |
| A1LN34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 20 REPR 1 COM NPV | BR | BRL | Oct 2020 |
Biography
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi ther...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 00:26 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.